In a proposed rule unveiled March 8 (81 Fed. Reg. 13230), CMS says it will test various Medicare Part B reimbursement models (see story, p. 1). The most widely reviled by stakeholders would change reimbursement from average sales price +6% to ASP +2.5% plus a payment of $16.80 per drug per day. SPN spoke with […]
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.